# gp100 (PMEL)

Source: https://onco.cc/targets/gp100/  
OnCo record `gp100` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

gp100 is a pigment-cell protein, and the target of the first bispecific drug to improve survival in a solid tumour, uveal melanoma.

## Summary

gp100 (PMEL) is a melanosomal matrix protein of the pigment-cell lineage, present in more than 90 percent of melanomas including uveal melanoma. It sits inside the cell and is presented on the surface only as peptide in HLA, so it is reached through T-cell receptor recognition rather than antibodies. Tebentafusp (Kimmtrak), an ImmTAC that fuses a high-affinity TCR against gp100/HLA-A*02:01 to an anti-CD3 effector, improved overall survival in metastatic uveal melanoma in the IMCgp100-202 trial, making it the first bispecific to improve survival in a solid tumour. Because normal skin melanocytes also carry gp100, rash is an expected on-target effect, and the HLA-A*02:01 restriction limits eligibility. Extending the approach to cutaneous melanoma is under study. The newcomer's version: gp100 is a pigment-cell protein that gave uveal melanoma its first life-extending drug.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: tcr-target
- Symbol: PMEL
- Class: other
- Biology: Melanosomal matrix protein; intracellular, presented on HLA.
- Where found: Melanoma including uveal

## Sources

- UniProt P40967: PMEL (gp100): https://www.uniprot.org/uniprotkb/P40967/entry

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Tebentafusp](https://onco.cc/drugs/tebentafusp/)
- trials: [IMCgp100-202](https://onco.cc/trials/imcgp100-202/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- people: [Paul Nathan](https://onco.cc/people/paul-nathan/), [Richard D. Carvajal](https://onco.cc/people/richard-carvajal/)
- pathways: [Antigen presentation & immune editing](https://onco.cc/pathways/antigen-presentation-immunoediting/)
- institutions: [Oxford Cancer (Oxford University Hospitals and University of Oxford)](https://onco.cc/institutions/oxford-cancer/)
- targets: [HLA-A](https://onco.cc/targets/hla-a/)

---
JSON: https://onco.cc/api/v1/entities/gp100.json